Phathom Pharmaceuticals Upgraded by Barclays to Overweight With $18 Target
Barclays analyst Jenna Davidner upgraded Phathom Pharmaceuticals (NASDAQ:PHAT) to Overweight from Equal Weight on Friday, raising her price target to $18 from $16. With the stock trading at $10.69 — down nearly 32% year-to-date…



















